Get answers to your heart-related questions from UM Heart Center experts.
Emergency treatment and hospitalization may be necessary. In cases of severe, life-threatening pulmonary embolism, definitive treatment may consist of dissolving the clot with thrombolytic therapy. Anticoagulant therapy prevents the formation of more clots and allows the body to re-absorb the existing clots faster.
Clot-dissolving medication (thrombolytic therapy) includes streptokinase, urokinase, or t-PA. Clot-preventing medication (anticoagulation therapy) consists of heparin by intravenous infusion initially, then oral warfarin (Coumadin). Subcutaneous low-molecular weight heparin is substituted for intravenous heparin in many circumstances. Patients who have reactions to heparin or related medications may need other medications.
Patients who cannot tolerate anticoagulation therapy may need an inferior vena cava filter (IVC filter). This device, placed in the main central vein in the abdomen, is designed to block large clots from traveling into the pulmonary vessels. Oxygen therapy may be required to maintain normal oxygen concentrations.
Surgery is sometimes needed in patients at great risk for recurrent embolism.
It is difficult to predict how the patient will do in the future. Often, the outlook is related to the disease that puts the person at risk for pulmonary embolism (for example, cancer, major surgery, trauma). In cases of severe pulmonary embolism, where shock and heart failure occur, the death rate may be greater than 50%.
Go to the emergency room or call the local emergency number (such as 911) if you have symptoms of pulmonary embolus.
Perrier A, Roy PM, Aujesky D, et al. Diagnosing pulmonary embolism in outpatients with clinical assessment, D-Dimer measurement, venous ultrasound, and helical computed tomography: a multicenter management study. Am J Med . March 2004;116:291-299.
Ramzi DW, Leeper KV. DVT and Pulmonary Embolism: Part II. Treatment and Prevention. Am Fam Physician . June 15 2004;69:2841-2848.
Merli G. Diagnostic assessment of deep vein thrombosis and pulmonary embolism. Am J Med . August 2005;118:3S-12S.
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch). |